Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Lokivetmab reduced itching in a dog with skin lymphoma.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Thiopurines help treat IBD but require genetic testing to avoid side effects.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

A cancer patient's hair became permanently curly after treatment with nivolumab.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.

Topical tacalcitol ointment can help improve symptoms of EFFC.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Oral tofacitinib successfully treated total body hair loss in one patient.

Upadacitinib may effectively treat resistant lichen planopilaris.

Omalizumab can cause temporary hair loss but still works well for chronic urticaria.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.